SCHEMBL13877952

SCHEMBL13877952

CC1(C)CC=C(c2cc([C@]3(O)C[C@@]4(CO[Si](C)(C)C(C)(C)C)C=C[C@@](CO[Si](C)(C)C(C)(C)C)(C3)O4)ccc2NC(=O)c2nc(C#N)c[nH]2)CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4231426 1.00 — —
SCHEMBL13877944 0.93 — —
SCHEMBL4235446 0.92 — —
SCHEMBL15139356 0.92 — —
SCHEMBL13877950 0.89 — —
SCHEMBL4231866 0.89 — —
SCHEMBL23808695 0.87 — —
SCHEMBL13877899 0.86 — —
SCHEMBL19264746 0.85 — —
SCHEMBL4238082 0.85 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8497376-B2 4-Cyano-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(2,6-dioxo-piperidin-4-yl)-phenyl]-amide; tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent JANSSEN PHARMACEUTICA N.V. (BE) 2013-07-30 — — US disclosed
US-20090105296-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2009-04-23 — — US disclosed
Send feedback